{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T19:03:39Z","timestamp":1789326219557,"version":"build-2803163510"},"reference-count":32,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu\u2010PSMA\u2010617 has been an approved treatment modality for metastatic castration\u2010resistant prostate cancer (mCRPC). Recent studies have shown PSMA upregulation following enzalutamide, which may enhance the outcomes with [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu\u2010PSMA\u2010617. This study aims to evaluate the efficacy and safety of short\u2010course enzalutamide priming with [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu\u2010PSMA\u2010617 in mCRPC patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This investigator\u2010initiated, single\u2010arm phase 2 trial recruited men with mCRPC, having progressed on \u2265one line of taxane and androgen\u2010receptor pathway inhibitors (ARPIs), and fit for [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu\u2010PSMA\u2010617. Enzalutamide (160\u2009mg\/day) was administered orally for 7 days before and after [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu\u2010PSMA\u2010617 (7.4\u2009GBq\/cycle, up to 6 cycles, at 6\u20138 week intervals). The primary end\u2010point was proportion of patients achieving \u2265\u200950% decline in prostate\u2010specific antigen (PSA50\u2010response rate, PSA50\u2010RR). A sample size of 20 patients was calculated using Simon's two\u2010stage design with at least 12\/20 PSA50\u2010responses required for rejection of null hypothesis. Secondary end\u2010points included objective radiographic response rate (ORR), PSA progression\u2010free survival (PSA\u2010PFS), radiographic PFS (rPFS), overall survival (OS), and adverse events (AEs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between May 2023 and January 2025, 20 mCRPC patients (median age 67 years) were enrolled. The PSA50\u2010RR was 40% (8\/20, 95% CI: 19\u201364), thus the null hypothesis was not rejected. The ORR was 25% (5\/20, 95% CI: 10\u201349). Over a median follow\u2010up of 24 months, median PSA\u2010PFS, rPFS, and OS were 4.0 months (95% CI: 3.0\u20137.5), 4.0 months (95% CI: 4.0\u20137.5), and 12.6 months (95% CI: 6.2\u201317.0), respectively. Grade 3 AEs were observed in four patients (20%, 95% CI: 6\u201344).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The addition of short\u2010course enzalutamide to [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu\u2010PSMA\u2010617 did not meaningfully improve treatment outcomes of taxane and ARPI\u2010exposed mCRPC patients in this trial.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>Clinical Trials Registry\u2010India, CTRI\/2023\/05\/053301. Registered 31 May 2023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pros.70253","type":"journal-article","created":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T18:15:42Z","timestamp":1789323342000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["[\n                    <sup>177<\/sup>\n                    Lu]Lu\u2010PSMA\u2010617 Plus Short\u2010Course Priming With Enzalutamide in Metastatic Castration\u2010Resistant Prostate Cancer: A Single\u2010Arm Phase 2 Trial (Lu\u2010PRIME)"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3067-3113","authenticated-orcid":false,"given":"Piyush","family":"Aggarwal","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine Post Graduate Institute of Medical Education and Research Chandigarh India"},{"name":"Department of Nuclear Medicine Sri Aurobindo Medical College and P. G. Institute, SAU Indore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7228-0361","authenticated-orcid":false,"given":"Ashwani","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Post Graduate Institute of Medical Education and Research Chandigarh India"},{"name":"Department of Nuclear Medicine Rohilkhand Medical College and Hospital Bareilly India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-6644","authenticated-orcid":false,"given":"Swayamjeet","family":"Satapathy","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Post Graduate Institute of Medical Education and Research Chandigarh India"},{"name":"Department of Nuclear Medicine Mahamana Pandit Madan Mohan Malaviya Cancer Centre &amp; Homi Bhabha Cancer Hospital, Tata Memorial Centre Varanasi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9972-6682","authenticated-orcid":false,"given":"Shikha","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Oncology Post Graduate Institute of Medical Education and Research Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komalpreet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Post Graduate Institute of Medical Education and Research Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4142-1592","authenticated-orcid":false,"given":"Gaurav","family":"Prakash","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology and Medical Oncology Post Graduate Institute of Medical Education and Research Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7440-0996","authenticated-orcid":false,"given":"Kannan","family":"Periasamy","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Oncology Post Graduate Institute of Medical Education and Research Chandigarh India"},{"name":"Department of Radiation Oncology Jawaharlal Institute of Postgraduate Medical Education and Research Puducherry India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-5783","authenticated-orcid":false,"given":"Bhagwant Rai","family":"Mittal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Post Graduate Institute of Medical Education and Research Chandigarh India"},{"name":"Department of Nuclear Medicine Mahatma Gandhi Medical College and Hospital, Mahatma Gandhi University of Medical Sciences and Technology Jaipur India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update","volume":"87","author":"Schafer E. J.","year":"2025","journal-title":"European Urology"},{"key":"e_1_2_10_3_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray F.","year":"2024","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium\u2010177\u2013PSMA\u2010617 for Metastatic Castration\u2010Resistant Prostate Cancer","volume":"385","author":"Sartor O.","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu\u2010PSMA\u2010617 Versus a Change of Androgen Receptor Pathway Inhibitor Therapy for Taxane\u2010Naive Patients With Progressive Metastatic Castration\u2010Resistant Prostate Cancer (PSMAfore): A Phase 3, Randomised, Controlled Trial","volume":"404","author":"Morris M. J.","year":"2024","journal-title":"Lancet"},{"key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.annonc.2025.07.003","article-title":"Final Overall Survival and Safety Analyses of the Phase III PSMAfore Trial of [177Lu]Lu\u2010PSMA\u2010617 Versus Change of Androgen Receptor Pathway Inhibitor in Taxane\u2010Naive Patients With Metastatic Castration\u2010Resistant Prostate Cancer","volume":"36","author":"Fizazi K.","year":"2025","journal-title":"Annals of Oncology"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga\u2010PSMA\u201011 PET and Clinical Outcomes in Metastatic Castration\u2010Resistant Prostate Cancer Following 177Lu\u2010PSMA\u2010617 (VISION Trial)","volume":"312","author":"Kuo P. H.","year":"2024","journal-title":"Radiology"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","article-title":"Influence of Androgen Deprivation Therapy on PSMA Expression and PSMA\u2010Ligand PET Imaging of Prostate Cancer Patients","volume":"47","author":"Vaz S.","year":"2020","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s13139-016-0439-4","article-title":"Influence of Androgen Deprivation Therapy on the Uptake of PSMA\u2010Targeted Agents: Emerging Opportunities and Challenges","volume":"51","author":"Bakht M. K.","year":"2017","journal-title":"Nuclear Medicine and Molecular Imaging"},{"key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.3390\/cancers14112691","article-title":"Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [177Lu]Lu\u2010PSMA\u2010617 Radioligand Therapy in mCRPC Patients With Imminent Treatment Failure\u2010Preliminary Evidence of Pilot Experience","volume":"14","author":"Rosar F.","year":"2022","journal-title":"Cancers"},{"key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"177Lu]Lu\u2010PSMA\u2010617 Plus Enzalutamide in Patients With Metastatic Castration\u2010Resistant Prostate Cancer (ENZA\u2010p): An Open\u2010Label, Multicentre, Randomised, Phase 2 Trial","volume":"25","author":"Emmett L.","year":"2024","journal-title":"Lancet Oncology"},{"key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","article-title":"Overall Survival and Quality of Life With [177Lu]Lu\u2010PSMA\u2010617 Plus Enzalutamide Versus Enzalutamide Alone in Metastatic Castration\u2010Resistant Prostate Cancer (ENZA\u2010p): Secondary Outcomes From a Multicentre, Open\u2010Label, Randomised, Phase 2 Trial","volume":"26","author":"Emmett L.","year":"2025","journal-title":"Lancet Oncology"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/pros.23522","article-title":"Pharmacological Upregulation of Prostate\u2010Specific Membrane Antigen (PSMA) Expression in Prostate Cancer Cells","volume":"78","author":"Kranzb\u00fchler B.","year":"2018","journal-title":"Prostate"},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.3390\/ijms22147431","article-title":"Enzalutamide Enhances Psma Expression of PSMA\u2010Low Prostate Cancer","volume":"22","author":"Staniszewska M.","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/pros.22910","article-title":"Synergistic Co\u2010Targeting of Prostate\u2010Specific Membrane Antigen and Androgen Receptor in Prostate Cancer","volume":"75","author":"Murga J. D.","year":"2015","journal-title":"Prostate"},{"key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/RLU.0000000000002585","article-title":"Increased PSMA Expression in Castration\u2010Resistant Prostate Cancer Metastases 3 Months After Initiation of Enzalutamide Indicated by 18F\u2010DCFPyL PET\/CT","volume":"44","author":"Wondergem M.","year":"2019","journal-title":"Clinical Nuclear Medicine"},{"key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1073\/pnas.1106383108","article-title":"Noninvasive Measurement of Androgen Receptor Signaling With a Positron\u2010Emitting Radiopharmaceutical That Targets Prostate\u2010Specific Membrane Antigen","volume":"108","author":"Evans M. J.","year":"2011","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/RLU.0000000000004529","article-title":"Increased PSMA Expression in 177Lu\u2010PSMA\u2010617 Scan in Metastatic Castrate\u2010Resistant Prostate Cancer Patient Treated With PSMA Radioligand Therapy and Enzalutamide: A Potential Game\u2010Changer","volume":"48","author":"Aggarwal P.","year":"2023","journal-title":"Clinical Nuclear Medicine"},{"key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.euo.2018.03.010","article-title":"Heterogeneous Flare in Prostate\u2010Specific Membrane Antigen Positron Emission Tomography Tracer Uptake With Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer","volume":"1","author":"Aggarwal R.","year":"2018","journal-title":"European Urology Oncology"},{"key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13550-018-0451-z","article-title":"Preclinical Evaluation of PSMA Expression in Response to Androgen Receptor Blockade for Theranostics in Prostate Cancer","volume":"8","author":"L\u00fcckerath K.","year":"2018","journal-title":"EJNMMI Research"},{"key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2967\/jnumed.118.223099","article-title":"Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga\u2010PSMA\u201011 PET in Men With Hormone\u2010Sensitive and Castrate\u2010Resistant Prostate Cancer Commencing Androgen Blockade","volume":"60","author":"Emmett L.","year":"2019","journal-title":"Journal of Nuclear Medicine"},{"key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13550-018-0386-4","article-title":"External Radiation Exposure, Excretion, and Effective Half\u2010Life in 177Lu\u2010PSMA\u2010Targeted Therapies","volume":"8","author":"Kurth J.","year":"2018","journal-title":"EJNMMI Research"},{"key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)","volume":"45","author":"Eisenhauer E. A.","year":"2009","journal-title":"European Journal of Cancer"},{"key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial Design and Objectives for Castration\u2010Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher H. I.","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_10_25_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal Two\u2010Stage Designs for Phase II Clinical Trials","volume":"10","author":"Simon R.","year":"1989","journal-title":"Controlled Clinical Trials"},{"key":"e_1_2_10_26_1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/biomedicines9040430","article-title":"177Lu\u2010PSMA Therapy in Metastatic Castration\u2010Resistant Prostate Cancer","volume":"9","author":"Sanli Y.","year":"2021","journal-title":"Biomedicines"},{"key":"e_1_2_10_27_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102398","article-title":"Safety and Efficacy of Lutetium\u2010177 PSMA Therapy for Metastatic Castration\u2010Resistant Prostate Cancer: A Systematic Review and Meta\u2010Analysis of Randomized Controlled Trials","volume":"23","author":"Belabaci Z.","year":"2025","journal-title":"Clinical Genitourinary Cancer"},{"key":"e_1_2_10_28_1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/03915603241249230","article-title":"Does Enzalutamide Related PSMA Upregulation Affect Outcomes of Lutetium\u2010177 PSMA Radioligand Therapy?","volume":"91","author":"Cengiz T. B.","year":"2024","journal-title":"Urologia Journal"},{"key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.euo.2025.06.004","article-title":"Outcomes for [177Lu]Lu\u2010PSMA\u2010617 With and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration\u2010Resistant Prostate Cancer","volume":"8","author":"Muniz M.","year":"2025","journal-title":"European Urology Oncology"},{"key":"e_1_2_10_30_1","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/RLU.0000000000003307","article-title":"Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration\u2010Resistant Prostate Cancer Treated With 177Lu\u2010Labeled Prostate\u2010Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta\u2010Analysis","volume":"45","author":"Satapathy S.","year":"2020","journal-title":"Clinical Nuclear Medicine"},{"key":"e_1_2_10_31_1","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1007\/s00259-021-05618-3","article-title":"177Lu\u2010PSMA\u2010617 Versus Docetaxel in Chemotherapy\u2010Na\u00efve Metastatic Castration\u2010Resistant Prostate Cancer: A Randomized, Controlled, Phase 2 Non\u2010Inferiority Trial","volume":"49","author":"Satapathy S.","year":"2021","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1007\/s00259-025-07082-9","article-title":"First Real\u2010World Clinical Experience With [(177)Lu]Lu\u2010PSMA\u2010I &;T in Patients With Metastatic Castration\u2010Resistant Prostate Cancer Beyond Vision and TheraP Criteria","volume":"52","author":"Ling S. W.","year":"2025","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"e_1_2_10_33_1","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.3390\/cancers15092592","article-title":"Tumor Sink Effect With Prostate\u2010Specific Membrane Antigen\u2010Targeted Theranostics in Patients With Metastatic Castration\u2010Resistant Prostate Cancer: Intra\u2010Individual Evaluations","volume":"15","author":"Burgard C.","year":"2023","journal-title":"Cancers"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.70253","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pros.70253","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.70253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T18:15:46Z","timestamp":1789323346000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.70253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,13]]},"references-count":32,"alternative-id":["10.1002\/pros.70253"],"URL":"https:\/\/doi.org\/10.1002\/pros.70253","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,13]]},"assertion":[{"value":"2026-07-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"pros.70253"}}